slides · global inventory
Frame Problem
Slide function collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 5,849
Current window 4,531-4,560
Pages 195
Rows per page 30
Slide function
4,531-4,560 of 5,849
08
The slide uses a comparison frame to contrast small molecule data availability with biologic data scarcity.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
03
Uses a rhetorical question to frame the company's value proposition as a paradigm shift.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
04
Uses a process diagram to illustrate the iterative, inefficient nature of traditional drug discovery.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
05
Uses a visual comparison between small molecule and biologic data availability to frame the problem.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Situation & Context1 hit
07
The slide uses a metaphor to frame the company's value proposition against the backdrop of low clinical trial success rates.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Solution & ApproachLoop · Golden Circle1 hit
05
The chart plots UC maintenance remission rates against maintenance dosing frequency, showing current standard-of-care drugs clustered at lower efficacy and higher frequency, while the 'Spyre Target' is positioned at higher efficacy and lower frequency.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
05
The chart is a scatter plot showing maintenance remission rates vs. dosing frequency, positioning current therapies in a cluster and the company's target in a superior quadrant.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
08
The diagram illustrates the interaction between T cells, tumor cells, and cytokines (IL-2, IL-12, IL-18) and the mechanism of checkpoint inhibitors.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
12
The slide uses a before-after framing to highlight the market opportunity.Apollo Global Management | Investor Day Presentation Deck | 119 slides · Apollo Global Management
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Tale Two Worlds1 hit
13
Apollo Global Management | Investor Day Presentation Deck | 119 slidesApollo Global Management | Investor Day Presentation Deck | 119 slides · Apollo Global Management
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Tale Two Worlds1 hit
07
Uses a geographic map and a nested circle diagram to illustrate the treatment gap.Arbutus Biopharma | Investor Presentation Deck | 25 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
04
The chart uses a 'Today' marker to emphasize the rapid growth phase.Astra | Investor Presentation Deck | 22 slides · Astra
Pitch deck Investor relations Beat · Problem1 hit
03
The slide uses a value-chain style diagram to show the flow of money and services between various intermediaries.Azerion | Investor Presentation Deck | 34 slides · Azerion
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
07
Exscientia | Investor Presentation Deck | 69 slidesExscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
22
The chart is a hierarchical clustering heatmap, commonly used in bioinformatics to show differential gene expression or patient response profiles.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle1 hit
59
Exscientia | Investor Presentation Deck | 69 slidesExscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle1 hit
03
Uses screenshots of competitor products with red circles highlighting disclaimers that they do not check for heart attacks.HeartBeam | Investor Presentation Deck | 18 slides · HeartBeam
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
04
Uses a binary choice framework to highlight the negative outcomes of patient uncertainty.HeartBeam | Investor Presentation Deck | 18 slides · HeartBeam
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
04
Uses a hub-and-spoke diagram to illustrate the central problem of CAR-T neurotoxicity and its four primary negative impacts.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
12
The slide uses a process flow diagram to illustrate the disease mechanism and a human anatomy diagram to show clinical manifestations.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Hypothesis Test1 hit
39
The slide uses a bubble chart to map clinical trials and a table to summarize drug performance metrics, highlighting low efficacy and high toxicity.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
11
Uses a visual timeline/process flow to explain the biological progression of CRC.Mainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
11
Uses a visual timeline/process flow to explain the disease progression.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
03
The slide uses a dramatic, urgent tone to frame the problem.Nemaura Medical | Investor Presentation Deck | 19 slides · Nemaura Medical
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
07
Uses a before-after-bridge framework to contrast existing therapy failure with Nuvalent's success.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
12
The slide uses a medical illustration to map specific TRK receptor inhibition side effects to anatomical locations.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
09
The slide uses a comparison framework to justify the use of alpha-emitting isotopes in targeted radiotherapy.RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank Beat · Problem1 hit
12
The slide uses a process flow diagram to show the standard of care progression for two types of NETs.RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank Beat · ProblemLoop · Cost Of Inaction1 hit
13
The slide uses a Kaplan-Meier curve to contrast Lutathera against a control group, highlighting the clinical limitation of the current standard of care.RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
11
Uses a 'Misconception vs. Real Issue' framework to pivot the narrative.VinFast | Investor Presentation Deck | 33 slides · VinFast
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit